(Q42510894)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Effect of ASCO/CAP guidelines for determining ER status on molecular subtype (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Brenda Deyarmin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Jennifer L Kane

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Allyson L Valente

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Christopher Gallagher

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Craig D Shriver

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Rachel E Ellsworth

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

9 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

Annals of Surgical Oncology

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

87-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22875649%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1245/s10434-012-2588-8

10 February 2020

exact match

0 references

cites work

Membrane-associated estrogen receptor signaling pathways in human cancers.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Steroid hormone receptors in breast cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

A gene expression signature identifies two prognostic subgroups of basal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Metastatic behavior of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Is gene array testing to be considered routine now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8

Hormone Receptors as Prognostic Factors in Female: Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2588-8